These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 28739492)
21. Benefits and harms of atypical antipsychotics for agitation in adults with dementia. Farlow MR; Shamliyan TA Eur Neuropsychopharmacol; 2017 Mar; 27(3):217-231. PubMed ID: 28111239 [TBL] [Abstract][Full Text] [Related]
22. Antipsychotic treatment of psychosis and agitation in the elderly. Daniel DG J Clin Psychiatry; 2000; 61 Suppl 14():49-52. PubMed ID: 11154017 [TBL] [Abstract][Full Text] [Related]
23. Agitation in nursing home residents with dementia (VIDEANT trial): effects of a cluster-randomized, controlled, guideline implementation trial. Rapp MA; Mell T; Majic T; Treusch Y; Nordheim J; Niemann-Mirmehdi M; Gutzmann H; Heinz A J Am Med Dir Assoc; 2013 Sep; 14(9):690-5. PubMed ID: 23827658 [TBL] [Abstract][Full Text] [Related]
24. Role of citalopram in the treatment of agitation in Alzheimer's disease. Porsteinsson AP; Keltz MA; Smith JS Neurodegener Dis Manag; 2014; 4(5):345-9. PubMed ID: 25405648 [TBL] [Abstract][Full Text] [Related]
25. [Safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms in dementia: a meta-analysis]. Xue XJ; He RL; Li WX; Xin JW; Ye QY; Chen XC; Pan XD Zhonghua Yi Xue Za Zhi; 2018 Jul; 98(25):2030-2036. PubMed ID: 29996606 [No Abstract] [Full Text] [Related]
26. Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study. De Deyn PP; Eriksson H; Svensson H; Int J Geriatr Psychiatry; 2012 Mar; 27(3):296-304. PubMed ID: 21538537 [TBL] [Abstract][Full Text] [Related]
27. Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. Verhey FR; Verkaaik M; Lousberg R; Dement Geriatr Cogn Disord; 2006; 21(1):1-8. PubMed ID: 16244481 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. Schneider LS; Tariot PN; Dagerman KS; Davis SM; Hsiao JK; Ismail MS; Lebowitz BD; Lyketsos CG; Ryan JM; Stroup TS; Sultzer DL; Weintraub D; Lieberman JA; N Engl J Med; 2006 Oct; 355(15):1525-38. PubMed ID: 17035647 [TBL] [Abstract][Full Text] [Related]
29. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication. Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660 [TBL] [Abstract][Full Text] [Related]
30. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease. Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682 [TBL] [Abstract][Full Text] [Related]
31. Citalopram in agitated and delusional demented patients who failed treatment with antipsychotic agents. Kotbi N; Singh A; Kneifati-Hayek J; Odom A; Alexopoulos G J Neuropsychiatry Clin Neurosci; 2014 Apr; 26(2):E62. PubMed ID: 24763800 [No Abstract] [Full Text] [Related]
32. When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram. Aga VM Am J Geriatr Psychiatry; 2019 Oct; 27(10):1099-1107. PubMed ID: 31288974 [TBL] [Abstract][Full Text] [Related]
34. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. Herrmann N; Cappell J; Eryavec GM; Lanctôt KL CNS Drugs; 2011 May; 25(5):425-33. PubMed ID: 21476613 [TBL] [Abstract][Full Text] [Related]
35. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Kurlan R; Cummings J; Raman R; Thal L; Neurology; 2007 Apr; 68(17):1356-63. PubMed ID: 17452579 [TBL] [Abstract][Full Text] [Related]
36. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
37. An update on the advancements in the treatment of agitation in Alzheimer's disease. Porsteinsson AP; Antonsdottir IM Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462 [TBL] [Abstract][Full Text] [Related]
38. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. Ballard C; Margallo-Lana M; Juszczak E; Douglas S; Swann A; Thomas A; O'Brien J; Everratt A; Sadler S; Maddison C; Lee L; Bannister C; Elvish R; Jacoby R BMJ; 2005 Apr; 330(7496):874. PubMed ID: 15722369 [TBL] [Abstract][Full Text] [Related]
39. Antipsychotics and the elderly. Kowatch JA Am J Nurs; 2009 Mar; 109(3):13-4. PubMed ID: 19240465 [No Abstract] [Full Text] [Related]
40. Effects of a Stepwise Multidisciplinary Intervention for Challenging Behavior in Advanced Dementia: A Cluster Randomized Controlled Trial. Pieper MJ; Francke AL; van der Steen JT; Scherder EJ; Twisk JW; Kovach CR; Achterberg WP J Am Geriatr Soc; 2016 Feb; 64(2):261-9. PubMed ID: 26804064 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]